Physician profile
Danielle Watts
NPI 1609608967
$3,348.42
in general payments reported to CMS, 2019-2025
41 companies · $2,801 in 2025
The $2,801 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $547 · 2025: $2,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,682 · Education: $666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,682.02 |
| Education | $666.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $364.33 | 2024-2025 | Verzenio, Jaypirca |
| Eisai INC. | $231.71 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $218.71 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Aveo Pharmaceuticals, INC. | $179.94 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $172.95 | 2024-2025 | |
| Daiichi Sankyo INC. | $171.97 | 2024-2025 | Enhertu, Datroway |
| Regeneron Pharmaceuticals, INC. | $149.00 | 2025 | Libtayo |
| Abbvie INC. | $148.16 | 2025 | |
| Sobi, INC | $142.73 | 2025 | |
| Janssen Biotech, INC. | $130.39 | 2024-2025 | Tecvayli, Darzalex, Erleada |
| Incyte Corporation | $105.08 | 2025 | Jakafi |
| Genzyme Corporation | $98.30 | 2025 | |
| Genentech USA, INC. | $82.10 | 2025 | Polivy, Phesgo, Venclexta |
| Array Biopharma INC | $78.15 | 2025 | Mektovi, Braftovi, Tukysa |
| Pfizer INC. | $75.53 | 2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.